Tetrahydrouridine/decitabine/5-azacytidine for Non-Cytotoxic Epigenetic-Immunotherapy of NSCLC in Vivo.
Kai Kang,Arjun Khunger,David S. Schrump,Mark P. Rubinstein,John M. Wrangle,Yogen Saunthararajah,Vamsidhar Velcheti
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e24134
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e24134 Background: Most advanced non-small cell lung cancer (NSCLC) cases do not respond to anti-PD1 therapy, because most NSCLC avoids immune-recognition in the 1st place, e.g, by epigenetic suppression of neo-antigen expression by DNA methyltransferase (DNMT1). DNMT1 is depleted by the clinical drugs decitabine (Dec) and 5-Azacytidine (5Aza), however, Dec/5Aza have trivial distribution into solid tissues because of rapid deamination by cytidine deaminase (CDA) in vivo, undermining application to treat NSCLC. We therefore combined a CDA inhibitor tetrahydrouridine (THU) with Dec/5Aza. Methods: Mice were inoculated with LL3-luc cells via tail vein (syngeneic) or patient tumor and PBMC via SC and tail vein (humanized PDX). Treatment with PBS (veh), THU-Dec/5Aza (10/0.1/1 mg/kg 3X/week), anti-PD1/Nivolumab (5 mg/kg ip q5d) or the combination was initiated after documentation of tumor engraftment (n = 5/group) Tumor burden, median survival (MS) were recorded. T-cell numbers/phenotype and drug PD were measured in blood and tumors. Results: Consistent with the pharmacologic rationale, THU-Dec/5Aza produced > 2-fold more DNMT1-depletion in tumor, and > 2-fold extension of MS, vs Dec or 5Aza alone. THU-Dec/5Aza or anti-PD1 alone increased MS vs PBS (THU-Dec/5Aza 60 d, anti-PD1 64 d, PBS 40 d), but strikingly, the combination produced cures. Immune-augmentation was demonstrated by > 5-fold increase in tumor infiltrating lymphocytes (TILs) with the combination vs PBS. An immune-basis for cures was confirmed by LL3-luc rechallenge, which did not engraft in surviving mice, but engrafted treatment naïve mice. Extending these results, in the humanized PDX, the combination again produced the greatest tumor regression (PBS 2.06 g, THU-Dec/5Aza 0.39 g, Nivolumab 0.54 g, combination 0.21 g). Again, TILs were increased ~5-fold with the combination vs PBS (p < 0.01). Also noted were significantly higher IFNγ, granzyme B, perforin expression in tumor 3.8, 4.2, 3.6-fold respectively vs PBS (p < 0.01). Conclusions: Combining THU with alternating Dec/5Aza realizes the value of DNMT1 as a molecular target that increases immune-recognition and destruction of NSCLC in vivo, scientific validation of our trial NCT02664181.